Medtronic PLC $MDT Shares Sold by Strs Ohio

Strs Ohio cut its holdings in shares of Medtronic PLC (NYSE:MDT) by 6.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 544,605 shares of the medical technology company’s stock after selling 34,705 shares during the period. Strs Ohio’s holdings in Medtronic were worth $52,315,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Artisan Partners Limited Partnership lifted its holdings in shares of Medtronic by 2.6% during the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after purchasing an additional 31,314 shares during the period. SageView Advisory Group LLC raised its position in Medtronic by 164.8% during the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after buying an additional 15,062 shares during the last quarter. CSM Advisors LLC raised its position in Medtronic by 13.2% during the 3rd quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after buying an additional 33,167 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Medtronic by 65.8% in the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after acquiring an additional 54,898 shares during the period. Finally, Applied Finance Capital Management LLC purchased a new stake in shares of Medtronic in the third quarter valued at about $1,308,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on MDT shares. Weiss Ratings lowered shares of Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, April 21st. Stifel Nicolaus reduced their price objective on shares of Medtronic from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Monday, April 6th. Daiwa Securities Group reduced their price objective on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Leerink Partners reiterated an “outperform” rating and set a $119.00 target price on shares of Medtronic in a research report on Tuesday, March 10th. Finally, William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $107.80.

Medtronic Stock Performance

NYSE:MDT opened at $80.02 on Friday. The firm’s fifty day simple moving average is $88.44 and its 200-day simple moving average is $94.82. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The stock has a market cap of $102.74 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 2.10 and a beta of 0.62. Medtronic PLC has a fifty-two week low of $78.91 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter last year, the business earned $1.38 earnings per share. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts expect that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.5%. Medtronic’s dividend payout ratio is currently 79.11%.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.26% of the stock is owned by insiders.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for the Stealth AXiS™ surgical system (spine & cranial); management frames the system as an integrated next‑generation navigation, planning and robotics platform that should help drive surgical growth and address hospital demand for consolidated systems. Medtronic plc (MDT) Receives the CE Mark for the Stealth AXiS™ Surgical System
• Positive Sentiment: CE mark in Europe for Stealth AXiS expands Medtronic’s addressable surgical market after earlier U.S. clearance — this supports the company’s surgical robotics/navigation growth story and creates new revenue opportunities in European hospitals. Medtronic’s Stealth AXiS Europe Approval Expands Surgical Growth Story
• Positive Sentiment: Progress on cardiac rhythm devices: Affera’s Sphere‑9 FDA Breakthrough designation and related CE activity for ablation catheters highlight Medtronic’s expanding pulsed‑field and RF ablation portfolio — could boost future electrophysiology revenue if trials and approvals continue to progress. Affera Breakthrough: FDA Nod For Sphere-9 Could Be A Game Changer For Medtronic (MDT)
• Positive Sentiment: FDA cleared a next‑generation mitral valve, and Medtronic has enrolled the first patient in a post‑approval study for the Altaviva tibial neuromodulation system — both items support incremental product revenue and clinical validation across cardiovascular and neuromodulation franchises. Medtronic wins FDA nod for next-gen mitral valve Medtronic enrolls first patient in post-approval study of Altaviva tibial neuromod
• Neutral Sentiment: Industry reports highlight wearable medical device market growth (Australia, Saudi Arabia) that could support long‑term opportunities for Medtronic’s wearable/remote monitoring initiatives, but these are broad market trends rather than company‑specific catalysts. Australia Wearable Medical Devices Market Trends and Forecasts Saudi Arabia Wearable Medical Devices Market Trends and Forecasts
• Neutral Sentiment: Competitor and sector moves — Masimo published a large real‑world study on pulse oximetry accuracy across skin tones; Teleflex named a new CEO; Orchestra BioMed received another FDA Breakthrough designation. These items influence competitive and regulatory context but are not direct Medtronic earnings drivers. Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones Teleflex Appoints Jason Weidman as President and CEO FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
• Negative Sentiment: Technical/market weakness: coverage noting MDT trading near multi‑month/1‑year lows highlights investor concern about valuation and near‑term momentum despite the product wins — this likely contributes to downward pressure on the stock. Medtronic Near Lows: S&P 500 Index Healthcare Story to Watch

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).